Comparison of treatment effect sizes from pivotal and postapproval trials of novel therapeutics approved by the FDA based on surrogate markers of disease: a meta-epidemiological study

BACKGROUND: The U.S. Food and Drug Administration (FDA) often approves new drugs based on trials that use surrogate markers for endpoints, which involve certain trade-offs and may risk making erroneous inferences about the medical product’s actual clinical effect. This study aims to compare the trea...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:BMC Med
Auteurs principaux: Wallach, Joshua D., Ciani, Oriana, Pease, Alison M., Gonsalves, Gregg S., Krumholz, Harlan M., Taylor, Rod S., Ross, Joseph S.
Format: Artigo
Langue:Inglês
Publié: BioMed Central 2018
Sujets:
Research Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5863466/
https://ncbi.nlm.nih.gov/pubmed/29562926
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12916-018-1023-9
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires